Technical Analysis for BDSX - Biodesix, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.25 | 5.04% | 0.06 |
BDSX closed down 4.03 percent on Wednesday, November 20, 2024, on 5.09 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 5.04% | |
| Expansion Breakdown | Bearish Swing Setup | 5.04% | |
| Volume Surge | Other | 5.04% | |
| New 52 Week Low | Weakness | 5.04% | |
| Wide Bands | Range Expansion | 5.04% | |
| Down 3 Days in a Row | Weakness | 5.04% | |
| Down 4 Days in a Row | Weakness | 5.04% | |
| Lower Bollinger Band Touch | Weakness | 5.04% | |
| Oversold Stochastic | Weakness | 5.04% | |
| Expansion Breakdown | Bearish Swing Setup | 0.81% |
| Alert | Time |
|---|---|
| Up 5% | about 3 hours ago |
| Up 3% | about 3 hours ago |
| Up 2% | about 3 hours ago |
| Up 1% | about 3 hours ago |
| Gap Down Closed | about 3 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/01/2024
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions. It also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated 2005 and is headquartered in Boulder, Colorado.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Clinical Research Lung Cancer Companion Diagnostic Diagnostic Solutions
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Clinical Research Lung Cancer Companion Diagnostic Diagnostic Solutions
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.21 |
| 52 Week Low | 1.11 |
| Average Volume | 337,188 |
| 200-Day Moving Average | 1.56 |
| 50-Day Moving Average | 1.59 |
| 20-Day Moving Average | 1.43 |
| 10-Day Moving Average | 1.33 |
| Average True Range | 0.10 |
| RSI (14) | 27.54 |
| ADX | 36.4 |
| +DI | 8.97 |
| -DI | 35.68 |
| Chandelier Exit (Long, 3 ATRs) | 1.43 |
| Chandelier Exit (Short, 3 ATRs) | 1.40 |
| Upper Bollinger Bands | 1.74 |
| Lower Bollinger Band | 1.12 |
| Percent B (%b) | 0.11 |
| BandWidth | 42.92 |
| MACD Line | -0.10 |
| MACD Signal Line | -0.08 |
| MACD Histogram | -0.0148 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.42 | ||||
| Resistance 3 (R3) | 1.42 | 1.34 | 1.38 | ||
| Resistance 2 (R2) | 1.34 | 1.28 | 1.34 | 1.37 | |
| Resistance 1 (R1) | 1.27 | 1.25 | 1.23 | 1.27 | 1.36 |
| Pivot Point | 1.19 | 1.19 | 1.17 | 1.19 | 1.19 |
| Support 1 (S1) | 1.11 | 1.13 | 1.07 | 1.11 | 1.02 |
| Support 2 (S2) | 1.03 | 1.09 | 1.03 | 1.01 | |
| Support 3 (S3) | 0.96 | 1.03 | 1.00 | ||
| Support 4 (S4) | 0.96 |
